Skip to main content
Erschienen in: Medical Oncology 2/2010

01.06.2010 | Original Paper

18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma

verfasst von: A. Azad, G. Chong, A. Tauro, A. Aly, N. C. Tebbutt

Erschienen in: Medical Oncology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

We present the case of a 65-year-old male with squamous cell carcinoma of the thoracic oesophagus on a background of neurofibromatosis type 1. On computed tomography, he was noted to have a large left-sided superior mediastinal mass. Initially, this mass was thought to be metastatic lymphadenopathy; however, it did not display fluorodeoxyglucose uptake on positron emission tomography. Subsequent biopsy confirmed the mass to be a neurofibroma and the patient commenced definitive chemo-radiation. Positron emission tomography had a major impact on management since the presumed lymph node disease was not included in the radiation field. In addition, positron emission tomography altered prognostic stratification since lymph node involvement is a poor prognostic factor in oesophageal cancer. We could only identify one other case in the English literature in which positron emission tomography was used to distinguish metastatic carcinoma from a neurofibroma, although there are a number of reports that describe the utility of positron emission tomography in differentiating benign neurofibromas from malignant connective tissue tumours.
Literatur
3.
Zurück zum Zitat Hsu CH, Lee CM, Wang FC, Fang CL. Neurofibroma with increased uptake of [F-18]-fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion. Ann Nucl Med. 2003;17(7):609–11. doi:10.1007/BF03006677.CrossRefPubMed Hsu CH, Lee CM, Wang FC, Fang CL. Neurofibroma with increased uptake of [F-18]-fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion. Ann Nucl Med. 2003;17(7):609–11. doi:10.​1007/​BF03006677.CrossRefPubMed
4.
5.
Zurück zum Zitat Minsky BD, et al. INT 0123 (Radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74. doi:10.1200/JCO.20.5.1167.CrossRefPubMed Minsky BD, et al. INT 0123 (Radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74. doi:10.​1200/​JCO.​20.​5.​1167.CrossRefPubMed
7.
Zurück zum Zitat Ferner RE, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390–4. doi:10.1093/annonc/mdm450.CrossRefPubMed Ferner RE, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390–4. doi:10.​1093/​annonc/​mdm450.CrossRefPubMed
9.
Zurück zum Zitat Ferner RE, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68(3):353–7. doi:10.1136/jnnp.68.3.353.CrossRefPubMed Ferner RE, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68(3):353–7. doi:10.​1136/​jnnp.​68.​3.​353.CrossRefPubMed
Metadaten
Titel
18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma
verfasst von
A. Azad
G. Chong
A. Tauro
A. Aly
N. C. Tebbutt
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9196-x

Weitere Artikel der Ausgabe 2/2010

Medical Oncology 2/2010 Zur Ausgabe

Letter to the editor

Letter to the editor

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.